Article information
Full text is only aviable in PDF
Biblografía
[1.]
S.E. Golditz, S.E. Hankinson, D.J. Hunter, W.C. Willett, J.E. Hanson, M.J. Stanpfer, et al.
The use of estrogens and progestins and the risk of breast cancer in posmenopausal women.
N Engl J Med, 332 (1995), pp. 1589-1593
[2.]
B. Ettinger.
Long-term postmenopausal estrogen. Therapy may be associated with increased risk of breast cancer.
A cohort study menopause, 4 (1997), pp. 125-129
[3.]
Beral V (Collaborative Group on Hormonal Factors in Breast Cancer).
Breast cancer and hormone replacement therapy: collaborative reanalysis of data from epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer.
Lancet, 350 (1997), pp. 1047-1059
[4.]
F.L. Lucas, J.A. Cauley, R.A. Stone, S.R. Cummings, M.T. Vogt, J.L. Weissfeld, et al.
Bone mineral density and risk of breast cancer. Study of Osteoporotic Fractures Research Group.
Am J Epidemiol, 148 (1998), pp. 122-129
[5.]
A.L. Fitzpatrick, J.R. Daling, C.D. Furberg, R.A. Kronmal, J.L. Weissfeld.
Use of calcium channel blockers and breast carcinoma risk in postmenopausal women.
Cancer, 80 (1997), pp. 1434-1447
[6.]
Design of the Women's Health Initiative clinical trial and observational study.
The Women's Health Initiative Group, 19 (1998), pp. 61-109
[7.]
P. Bonnier, F. Bessenay, A.J. Sasco, B. Beedassy, C. Lejeune, S. Roman, et al.
Impact of menopausal hormone-replacement therapy on clinical and laboratory characteristics of breast cancer.
Int J Cancer, 79 (1998), pp. 278-282
[8.]
R. Santen, K. Pritchard, M. Burger.
The Consensus Conference on treatment of estrogen deficiency symptoms in women surviving breast cancer.
Obs Gyn Surv, 53 (1998), pp. 1-83
Copyright © 2000. Elsevier España, S.L. y Sociedad Española de Medicina Rural y Generalista (SEMERGEN)
